# 1 Novel risk loci for COVID-19 hospitalization among

# 2 admixed American populations

3	Silvia Diz-de Almeida, <sup>1,2,13,7</sup> Raquel Cruz, <sup>1,2,13,7</sup> Andre D. Luchessi, <sup>3</sup> José M. Lorenzo-Salazar, <sup>4</sup>
4	Miguel López de Heredia, <sup>2</sup> Inés Quintela, <sup>5</sup> Rafaela González-Montelongo, <sup>4</sup> Vivian N. Silbiger, <sup>3</sup>
5	Marta Sevilla Porras, <sup>2,6</sup> Jair Antonio Tenorio Castaño, <sup>2,6,7</sup> Julian Nevado, <sup>2,6,7</sup> Jose María
6	Aguado, <sup>8,9,10,11</sup> Carlos Aguilar, <sup>12</sup> Sergio Aguilera-Albesa, <sup>13,14</sup> Virginia Almadana, <sup>15</sup> Berta
7	Almoguera, <sup>16,2</sup> Nuria Alvarez, <sup>17</sup> Álvaro Andreu-Bernabeu, <sup>18,10</sup> Eunate Arana-Arri, <sup>19,20</sup> Celso
8	Arango, <sup>18,21,10</sup> María J. Arranz, <sup>22</sup> Maria-Jesus Artiga, <sup>23</sup> Raúl C. Baptista-Rosas, <sup>24,25,26</sup> María
9	Barreda- Sánchez, <sup>27,28</sup> Moncef Belhassen-Garcia, <sup>29,30</sup> Joao F. Bezerra, <sup>31</sup> Marcos A.C. Bezerra, <sup>32</sup>
10	Lucía Boix-Palop, <sup>33</sup> María Brion, <sup>34,35</sup> Ramón Brugada, <sup>36,37,35,38</sup> Matilde Bustos, <sup>39</sup> Enrique J.
11	Calderón, <sup>39,40,41</sup> Cristina Carbonell, <sup>42,30</sup> Luis Castano, <sup>19,43,2,44,45</sup> Jose E. Castelao, <sup>46</sup> Rosa Conde-
12	Vicente, <sup>47</sup> M. Lourdes Cordero-Lorenzana, <sup>48</sup> Jose L. Cortes-Sanchez, <sup>49,50,</sup> Marta Corton, <sup>16,2</sup> M.
13	Teresa Darnaude, <sup>51</sup> Alba De Martino-Rodríguez, <sup>52,53</sup> Victor del Campo-Pérez, <sup>54</sup> Aranzazu Diaz
14	de Bustamante, <sup>51</sup> Elena Domínguez-Garrido, <sup>55</sup> Rocío Eirós, <sup>56</sup> María Carmen Fariñas, <sup>57,58,59</sup>
15	María J. Fernandez-Nestosa <sup>60</sup> Uxía Fernández-Robelo, <sup>61</sup> Amanda Fernández-Rodríguez, <sup>62,11</sup>
16	Tania Fernández-Villa, <sup>63,41</sup> Manuela Gago-Domínguez, <sup>5,64</sup> Belén Gil-Fournier, <sup>65</sup> Javier Gómez-
17	Arrue, <sup>52,53</sup> Beatriz González Álvarez, <sup>52,53</sup> Fernan Gonzalez Bernaldo de Quirós, <sup>66</sup> Anna
18	González-Neira, <sup>17</sup> Javier González-Peñas, <sup>18,10,21</sup> Juan F. Gutiérrez-Bautista, <sup>67</sup> María José
19	Herrero, <sup>68,69</sup> Antonio Herrero-Gonzalez, <sup>70</sup> María A. Jimenez-Sousa, <sup>62,11</sup> María Claudia Lattig, <sup>71,72</sup>
20	Anabel Liger Borja, <sup>73</sup> Rosario Lopez-Rodriguez, <sup>16,2,74</sup> Esther Mancebo, <sup>75,76</sup> Caridad Martín-
21	López, <sup>73</sup> Vicente Martín, <sup>63 41</sup> Oscar Martinez-Nieto, <sup>77,72</sup> Iciar Martinez-Lopez, <sup>78,79</sup> Michel F.
22	Martinez-Resendez, <sup>49</sup> Ángel Martinez-Perez, <sup>80</sup> Juliana F. Mazzeu, <sup>81,82,83</sup> Eleuterio Merayo
23	Macías, <sup>84</sup> Pablo Minguez, <sup>16,2</sup> Victor Moreno Cuerda, <sup>85,86</sup> Silviene F. Oliveira, <sup>87,88,83,89</sup> Eva
24	Ortega-Paino, <sup>23</sup> Mara Parellada, <sup>18,21,10</sup> Estela Paz-Artal, <sup>75,76,90</sup> Ney P.C. Santos, <sup>91</sup> Patricia Pérez-
25	Matute, <sup>92</sup> Patricia Perez, <sup>93</sup> M. Elena Pérez-Tomás, <sup>27</sup> Teresa Perucho, <sup>94</sup> Mel·lina Pinsach-
26	Abuin, <sup>36,35</sup> Guillermo Pita, <sup>17</sup> Ericka N. Pompa-Mera, <sup>95,96</sup> Gloria L. Porras-Hurtado, <sup>97</sup> Aurora

27	Pujol, <sup>98,2,99</sup> Soraya Ramiro León, <sup>65</sup> Salvador Resino, <sup>62,11</sup> Marianne R. Fernandes, <sup>91,100</sup> Emilio
28	Rodríguez-Ruiz, <sup>101,64</sup> Fernando Rodriguez-Artalejo, <sup>102,103,41,104</sup> José A. Rodriguez-Garcia, <sup>105</sup>
29	Francisco Ruiz-Cabello, <sup>67,106,107</sup> Javier Ruiz-Hornillos, <sup>108,109,110</sup> Pablo Ryan, <sup>111,112,113,11</sup> José
30	Manuel Soria, <sup>80</sup> Juan Carlos Souto, <sup>114</sup> Eduardo Tamayo, <sup>115,116,11</sup> Alvaro Tamayo-Velasco, <sup>117</sup>
31	Juan Carlos Taracido-Fernandez, <sup>70</sup> Alejandro Teper, <sup>118</sup> Lilian Torres-Tobar, <sup>119</sup> Miguel
32	Urioste, <sup>120</sup> Juan Valencia-Ramos, <sup>121</sup> Zuleima Yáñez, <sup>122</sup> Ruth Zarate, <sup>123</sup> Itziar de Rojas, <sup>124,125</sup>
33	Agustín Ruiz, <sup>124,125</sup> Pascual Sánchez, <sup>126</sup> Luis Miguel Real, <sup>127</sup> SCOURGE Cohort Group, Encarna
34	Guillen-Navarro, <sup>27,128,129,130</sup> Carmen Ayuso, <sup>16,2</sup> Esteban Parra, <sup>131</sup> José A. Riancho, <sup>57,58,59,2</sup>
35	Augusto Rojas-Martinez, <sup>132</sup> Carlos Flores, <sup>4,133,134,135,136,*</sup> Pablo Lapunzina, <sup>2,6,7,136</sup> Ángel
36	Carracedo, <sup>1,2,5,64,136,</sup> **
37	Affiliations
20	<sup>1</sup> Centro Singular de Investigación en Medicina Molecular y Enfermedados Crónicas (CIMUS)
20	, Centro Singular de Investigación en Medicina Molecular y Emerinedades Ciónicas (ChviOS),
39	Universidade de Santiago de Compostela, Santiago de Compostela, Spain
40	<sup>2</sup> , CIBERER, ISCIII, Madrid, Spain
41	<sup>3</sup> , Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e
42	Toxicologicas, Natal, Brazil
43	<sup>4</sup> , Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife,
44	Spain
45	<sup>5</sup> , Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)
46	Santiago de Compostela, Spain
47	<sup>6</sup> , Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-
48	IDIPAZ, Madrid, Spain
49	<sup>7</sup> , ERN-ITHACA-European Reference Network
50	<sup>8</sup> , Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación
51	Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
52	<sup>9</sup> , Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de
53	Salud Carlos III, Madrid, Spain

- <sup>10</sup>, School of Medicine, Universidad Complutense, Madrid, Spain
- 55 <sup>11</sup>, CIBERINFEC, ISCIII, Madrid, Spain
- <sup>12</sup>, Hospital General Santa Bárbara de Soria, Soria, Spain
- <sup>13</sup>, Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,
- 58 Pamplona, Spain
- <sup>14</sup>, Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
- 60 <sup>15</sup>, Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
- 61 <sup>16</sup>, Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez
- 62 Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 63 <sup>17</sup>, Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
- <sup>18</sup>, Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,
- 65 Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 66 <sup>19</sup>, Biocruces Bizkai HRI, Bizkaia, Spain
- 67 <sup>20</sup>, Cruces University Hospital, Osakidetza, Bizkaia, Spain
- <sup>21</sup>, Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud
- 69 Carlos III, Madrid, Spain
- 70 <sup>22</sup>, Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
- 71 <sup>23</sup>, Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
- 72 <sup>24</sup>, Hospital General de Occidente, Zapopan Jalisco, Mexico
- 73 <sup>25</sup>, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá Jalisco, Mexico
- <sup>26</sup>, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá
- 75 Jalisco, Mexico
- 76 <sup>27</sup>, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
- <sup>28</sup>, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
- <sup>29</sup>, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de
- 79 Enfermedades Infecciosas, Salamanca, Spain
- 80 <sup>30</sup>, Universidad de Salamanca, Salamanca, Spain
- 81 <sup>31</sup>, Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Brazil

- <sup>32</sup>, Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
- 83 <sup>33</sup>, Hospital Universitario Mutua Terrassa, Barcelona, Spain
- <sup>34</sup>, Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de
- 85 Compostela, Spain
- 86 <sup>35</sup>, CIBERCV, ISCIII, Madrid, Spain
- 87 <sup>36</sup>, Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,
- 88 Spain
- <sup>37</sup>, Medical Science Department, School of Medicine, University of Girona, Girona, Spain
- 90 <sup>38</sup>, Hospital Josep Trueta, Cardiology Service, Girona, Spain
- <sup>39</sup>, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
- 92 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- <sup>40</sup>, Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,
- 94 Seville, Spain
- 95<sup>41</sup>, CIBERESP, ISCIII, Madrid, Spain
- 96 <sup>42</sup>, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,
- 97 Spain
- 98 <sup>43</sup>, Osakidetza, Cruces University Hospital, Bizkaia, Spain
- 99 <sup>44</sup>, Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases
- 100 (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- 101 <sup>45</sup>, University of Pais Vasco, UPV/EHU, Bizkaia, Spain
- <sup>46</sup>, Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de
- 103 Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- <sup>47</sup>, Hospital Universitario Río Hortega, Valladolid, Spain
- 105 <sup>48</sup>, Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña
- 106 (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- <sup>49</sup>, Tecnológico de Monterrey, Monterrey, Mexico
- <sup>50</sup>, Otto von Guericke University, Departament of Microgravity and Translational Regenerative
- 109 Medicine, Magdeburg, Germany

- 110 <sup>51</sup>, Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain
- <sup>52</sup>, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
- 112 <sup>53</sup>, Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
- 113 <sup>54</sup>, Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia
- 114 de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 115 <sup>55</sup>, Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
- <sup>56</sup>, Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
- 117 <sup>57</sup>, IDIVAL, Cantabria, Spain
- <sup>58</sup>, Universidad de Cantabria, Cantabria, Spain
- <sup>59</sup>, Hospital U M Valdecilla, Cantabria, Spain
- 120<sup>60</sup>, Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay
- 121 <sup>61</sup>, Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),
- 122 Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 123 <sup>62</sup>, Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
- 124 de Salud Carlos III (ISCIII), Madrid, Spain
- 125 <sup>63</sup>, Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) Instituto de
- 126 Biomedicina (IBIOMED), Universidad de León, León, Spain
- 127 <sup>64</sup>, IDIS
- 128 <sup>65</sup>, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain
- 129<sup>66</sup>, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina
- 130 <sup>67</sup>, Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,
- 131 Granada, Spain
- 132 <sup>68</sup>, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain
- 133 <sup>69</sup>, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain
- 134 <sup>70</sup>, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 135 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 136 <sup>71</sup>, Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia

- 137 <sup>72</sup>, SIGEN Alianza Universidad de los Andes Fundación Santa Fe de Bogotá, Bogotá,
- 138 Colombia
- 139<sup>73</sup>, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain
- 140 <sup>74</sup>, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización
- 141 Montepríncipe, 28660 Boadilla del Monte, España
- 142 <sup>75</sup>, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain
- 143 <sup>76</sup>, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant
- 144 Immunology and Immunodeficiencies Group, Madrid, Spain
- 145 <sup>77</sup>, Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios, Bogotá, Colombia
- 146 <sup>78</sup>, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain
- <sup>79</sup>, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,
- 148 Islas Baleares, Spain
- 149<sup>80</sup>, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant
- 150 Pau, IIB Sant Pau, Barcelona, Spain
- <sup>81</sup>, Universidade de Brasília, Faculdade de Medicina, Brazil
- 152 <sup>82</sup>, Programa de Pós-Graduação em Ciências Médicas (UnB), Brazil
- 153 <sup>83</sup>, Programa de Pós-Graduação em Ciencias da Saude (UnB), Brazil
- 154 <sup>84</sup>, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
- 155 <sup>85</sup>, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain
- 156 <sup>86</sup>, Universidad Francisco de Vitoria, Madrid, Spain
- 157 <sup>87</sup>, Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de
- 158 Brasília, Brazil
- 159 <sup>88</sup>, Programa de Pós-Graduação em Biologia Animal (UnB), Brazil
- 160 <sup>89</sup>, Programa de Pós-Graduação Profissional em Ensino de Biologia (UnB), Brazil
- <sup>90</sup>, Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT,
- 162 Madrid, Spain
- <sup>91</sup>, Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil

- <sup>92</sup>, Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for
- 165 Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 166 <sup>93</sup>, Inditex, A Coruña, Spain
- 167 <sup>94</sup>, GENYCA, Madrid, Spain
- 168 <sup>95</sup>, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad
- 169 de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico
- 170 <sup>96</sup>, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional La Raza. Hospital de
- 171 Infectología, Mexico City, Mexico
- <sup>97</sup>, Clinica Comfamiliar Risaralda, Pereira, Colombia
- <sup>98</sup>, Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,
- 174 L'Hospitalet de Llobregat, Spain
- <sup>99</sup>, Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- 176 <sup>100</sup>, Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
- 177 <sup>101</sup>, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),
- 178 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain
- 179 <sup>102</sup>, Department of Preventive Medicine and Public Health, School of Medicine, Universidad
- 180 Autónoma de Madrid, Madrid, Spain
- 181 <sup>103</sup>, IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain
- 182 <sup>104</sup>, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
- 183 <sup>105</sup>, Complejo Asistencial Universitario de León, León, Spain
- 184 <sup>106</sup>, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain
- 185 <sup>107</sup>, Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,
- 186 Granada, Spain
- 187 <sup>108</sup>, Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain
- 188 <sup>109</sup>, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -
- 189 Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 190 <sup>110</sup>, Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
- 191 <sup>111</sup>, Hospital Universitario Infanta Leonor, Madrid, Spain

- 192 <sup>112</sup>, Complutense University of Madrid, Madrid, Spain
- 193 <sup>113</sup>, Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
- <sup>114</sup>, Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
- 195 Barcelona, Spain
- 196 <sup>115</sup>, Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación,
- 197 Valladolid, Spain
- 198 <sup>116</sup>, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain
- 199 <sup>117</sup>, Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia,
- 200 Valladolid, Spain
- 201 <sup>118</sup>, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
- 202 <sup>119</sup>, Fundación Universitaria de Ciencias de la Salud
- 203 <sup>120</sup>, Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain
- 204 <sup>121</sup>, University Hospital of Burgos, Burgos, Spain
- 205 <sup>122</sup>, Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia
- 206 <sup>123</sup>, Centro para el Desarrollo de la Investigación Científica, Paraguay
- 207 <sup>124</sup>, Research Center and Memory clinic, ACE Alzheimer Center Barcelona, Universitat
- 208 Internacional de Catalunya, Spain
- 209 <sup>125</sup>, Centre for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED),
- 210 Instituto de Salud Carlos III, Madrid, Spain
- 211 <sup>126</sup>, CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain
- 212 <sup>127</sup>, Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas y
- 213 Microbiología, Sevilla, Spain
- 214 <sup>128</sup>, Sección Genética Médica Servicio de Pediatría, Hospital Clínico Universitario Virgen de la
- 215 Arrixaca, Servicio Murciano de Salud, Murcia, Spain
- 216 <sup>129</sup>, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,
- 217 Universidad de Murcia (UMU), Murcia, Spain
- 218 <sup>130</sup>, Grupo Clínico Vinculado, Centre for Biomedical Network Research on Rare Diseases
- 219 (CIBERER), Instituto de Salud Carlos III, Madrid, Spain

- <sup>131</sup> Department of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario,
- 221 Canada.
- <sup>132</sup>, Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey, Mexico
- 223 <sup>133</sup>, Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de
- 224 Investigación Sanitaria de Canarias, Santa Cruz de Tenerife, Spain
- <sup>134</sup>, Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de
- 226 Salud Carlos III, Madrid, Spain
- 227 <sup>135</sup>, Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran
- 228 Canaria, Spain
- 229 <sup>136</sup>, These authors contributed equally: Carlos Flores, Pablo Lapunzina, Ángel Carracedo
- 230 <sup>137</sup>, These authors contributed equally: Silvia Diz-de Almeida, Raquel Cruz
- 231 \*Correspondence:
- 232 \*\*Correspondence: <u>angel.carracedo@usc.es</u>
- 233

#### 234 Abstract

The genetic basis of severe COVID-19 has been thoroughly studied, and many genetic 235 236 risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific 237 common risk loci. In this second study nested in the SCOURGE consortium, we 238 239 conducted a GWAS for COVID-19 hospitalization in admixed Americans, comprising a total of 4,702 hospitalized cases recruited by SCOURGE and seven other participating 240 studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide 241 242 significant associations, two of which constitute novel loci and were first discovered in 243 Latin American populations (BAZ2B and DDIAS). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in CREBBP. Finally, we assessed the 244

performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort. This study constitutes the largest GWAS for COVID-19 hospitalization in admixed Latin Americans conducted to date. This allowed to reveal novel risk loci and emphasize the need of considering the diversity of populations in genomic research.

#### 250 Introduction

251 To date, more than 50 loci associated with COVID-19 susceptibility, hospitalization, and severity have been identified using genome-wide association studies  $(GWAS)^{1,2}$ . 252 The COVID-19 Host Genetics Initiative (HGI) has made significant efforts<sup>3</sup> to augment 253 254 the power to identify disease loci by recruiting individuals from diverse populations and 255 conducting a trans-ancestry meta-analysis. Despite this, the lack of genetic diversity and a focus on cases of European ancestries still predominate in the studies<sup>4,5</sup>. In addition, 256 257 while trans-ancestry meta-analyses are a powerful approach for discovering shared genetic risk variants with similar effects across populations<sup>6</sup>, they may fail to identify 258 259 risk variants that have larger effects on particular underrepresented populations. Genetic disease risk has been shaped by the particular evolutionary history of populations and 260 environmental exposures<sup>7</sup>. Their action is particularly important for infectious diseases 261 due to the selective constraints that are imposed by host  $\Box$  pathogen interactions<sup>8,9</sup>. 262 263 Literature examples of this in COVID-19 severity include a DOCK2 gene variant in East Asians<sup>10</sup> and frequent loss-of-function variants in IFNAR1 and IFNAR2 genes in 264 Polynesian and Inuit populations, respectively<sup>11,12</sup>. 265

Including diverse populations in case □ control GWAS studies with unrelated participants usually requires a prior classification of individuals in genetically homogeneous groups, which are typically analyzed separately to control the population stratification effects<sup>13</sup>. Populations with recent admixture impose an additional

270 challenge to GWASs due to their complex genetic diversity and linkage disequilibrium (LD) patterns, requiring the development of alternative approaches and a careful 271 inspection of results to reduce false positives due to population structure<sup>7</sup>. In fact, there 272 are benefits in study power from modeling the admixed ancestries either locally, at the 273 274 regional scale in the chromosomes, or globally, across the genome, depending on 275 factors such as the heterogeneity of the risk variant in frequencies or the effects among the ancestry strata<sup>14</sup>. Despite the development of novel methods specifically tailored for 276 the analysis of admixed populations<sup>15</sup>, the lack of a standardized analysis framework 277 278 and the difficulties in confidently clustering admixed individuals into particular genetic 279 groups often leads to their exclusion from GWAS.

The Spanish Coalition to Unlock Research on Host Genetics on COVID-19 280 281 (SCOURGE) recruited COVID-19 patients between March and December 2020 from 282 hospitals across Spain and from March 2020 to July 2021 in Latin America (https://www.scourge-covid.org). A first GWAS of COVID-19 severity among Spanish 283 284 patients of European descent revealed novel disease loci and explored age- and sexvarying effects of genetic factors<sup>16</sup>. Here, we present the findings of a GWAS meta-285 analysis in admixed Latin American (AMR) populations, comprising individuals from 286 287 the SCOURGE Latin-American cohort and the HGI studies, which allowed us to identify two novel severe COVID-19 loci, BAZ2B and DDIAS. Further analyses 288 289 modeling the admixture from three genetic ancestral components and performing a 290 trans-ethnic meta-analysis led to the identification of an additional risk locus near 291 *CREBBP.* We finally assessed a cross-ancestry polygenic risk score model with variants 292 associated with critical COVID-19.

#### 293 **Results**

#### 294 Meta-analysis of COVID-19 hospitalization in admixed Americans

#### 295 Study cohorts

296 Within the SCOURGE consortium, we included 1,608 hospitalized cases and 1,887 controls (not hospitalized COVID-19 patients) from Latin American countries and from 297 recruitments of individuals of Latin American descent conducted in Spain 298 299 (Supplementary Table 1). Quality control details and estimation of global genetic 300 inferred ancestry (GIA) (Supplementary Figure 1) are described in Methods, whereas 301 clinical and demographic characteristics of patients included in the analysis are shown 302 in Table 1. Summary statistics from the SCOURGE cohort were obtained under a 303 logistic mixed model with the SAIGE model (Methods). Another seven studies 304 participating in the COVID-19 HGI consortium were included in the meta-analysis of 305 COVID-19 hospitalization in admixed Americans (Figure 1).

#### 306 GWAS meta-analysis

We performed a fixed-effects GWAS meta-analysis using the inverse of the variance as weights for the overlapping markers. The combined GWAS sample size consisted of

309 4,702 admixed AMR hospitalized cases and 68,573 controls.

This GWAS meta-analysis revealed genome-wide significant associations at four risk loci (Table 2, Figure 2), two of which (*BAZ2B* and *DDIAS*) were novel discoveries. Four lead variants were identified, linked to other 310 variants (Supplementary Tables 2-3). A gene-based association test revealed a significant association in *BAZ2B* and in previously known COVID-19 risk loci: *LZTFL1*, *XCR1*, *FYCO1*, *CCR9*, and *IFNAR2* (Supplementary Table 4).

Located within the *BAZ2B* gene, the sentinel variant rs13003835 is an intronic variant associated with an increased risk of COVID-19 hospitalization (Odds Ratio [OR]=1.20, 95% Confidence Interval [CI]=1.12-1.27, p= $3.66 \times 10^{-8}$ ). This association was not

medRxiv preprint doi: https://doi.org/10.1101/2023.08.11.23293871; this version posted July 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

319	previously reported in any GWAS of COVID-19 published to date. Interestingly,
320	rs13003835 did not reach significance (p=0.972) in the COVID-19 HGI trans-ancestry
321	meta-analysis including the five population groups <sup>1</sup> .
322	The other novel risk locus is led by the sentinel variant rs77599934, a rare intronic
323	variant located in chromosome 11 within DDIAS and associated with the risk of
324	COVID-19 hospitalization (OR=2.27, 95% CI=1.70-3.04, p=2.26x10 <sup>-8</sup> ).

- 325 We also observed a suggestive association with rs2601183 in chromosome 15, which is
- 326 located between ZNF774 and IOGAP1 (allele-G OR=1.20, 95% CI=1.12-1.29,
- $p=6.11 \times 10^{-8}$ , see Supplementary Table 2), which has not yet been reported in any other 327
- 328 GWAS of COVID-19 to date.

- The GWAS meta-analysis also pinpointed two significant variants at known loci, 329 LZTFL1 and FOXP4. The SNP rs35731912 was previously associated with COVID-19 330 severity in EUR populations<sup>17</sup>, and it was mapped to LZTFL1. While rs2477820 is a 331 novel risk variant within the FOXP4 gene, it has a moderate LD ( $r^2=0.295$ ) with 332 rs2496644, which has been linked to COVID-19 hospitalization<sup>18</sup>. This is consistent 333 with the effects of LD in tag-SNPs when conducting GWAS in diverse populations. 334
- 335 None of the lead variants was associated with the comorbidities included in Table 1.
- **Functional mapping of novel risk variants** 336

337 Variants belonging to the lead loci were prioritized by positional and expression quantitative trait loci (eOTL) mapping with FUMA, resulting in 31 mapped genes 338 339 (Supplementary Table 5). Within the region surrounding the lead variant in 340 chromosome 2, FUMA prioritized four genes in addition to BAZ2B (PLA2R1, LY75, 341 WDSUB1, and CD302). rs13003835 (allele C) is an eQTL of LY75 in the esophagus mucosa (NES=0.27) and of BAZ2B-AS in whole blood (NES=0.27), while rs2884110 342

343 ( $R^2=0.85$ ) is an eQTL of *LY75* in lung (NES=0.22). As for the chromosome 11, 344 rs77599934 (allele G) is in moderate-to-strong LD ( $r^2=0.776$ ) with rs60606421 (G 345 deletion, allele -) which is an eQTL associated with a reduced expression of *DDIAS* in 346 the lungs (NES=-0.49, allele -). Associations with expression are shown in the 347 supplementary Figure 4. The sentinel variant for the region in chromosome 16 is in 348 perfect LD ( $r^2=1$ ) with rs601183, an eQTL of *ZNF774* in the lung.

### 349 Bayesian fine mapping

350 We performed different approaches to narrow down the prioritized loci to a set of most 351 likely genes driving the associations. First, we computed credible sets at the 95% 352 confidence level for causal variants and annotated them with VEP (and V2G aggregate 353 scoring. The 95% confidence credible set from the region of chromosome 2 around 354 rs13003835 included 76 variants, which can be found in the Supplementary Table 6 (VEP and V2G annotations are included in the Supplementary Tables 7 and 8). The V2G 355 356 score prioritized BAZ2B as the most likely gene driving the association. However, the 357 approach was unable to converge allocating variants in a 95% confidence credible set for the region in chromosome 11. 358

#### 359 *Transcriptome-wide association study (TWAS)*

Five novel genes, namely, *SLC25A37*, *SMARCC1*, *CAMP*, *TYW3*, and *S100A12* (supplementary Table 9), were found to be significantly associated in the cross-tissue TWAS. To our knowledge, these genes have not been reported previously in any COVID-19 TWAS or GWAS analyses published to date. In the single tissue analyses, *ATP50* and *CXCR6* were significantly associated in the lungs, *CCR9* was significantly associated in whole blood, and *IFNAR2* and *SLC25A37* were associated in lymphocytes.

366	Likewise, we carried out TWAS analyses using the models trained in the admixed
367	populations. However, no significant gene pairs were detected in this case. The top 10
368	genes with the lowest p-values for each of the datasets (Puerto-Ricans, Mexicans,
369	African-Americans and pooled cohorts) are shown in the Supplementary Table 10.
370	Although not significant, KCNC3 was repeated in the four analyses, whereas
371	MAPKAPK3, NAPSA and THAP5 were repeated in 3 out of 4. Both NAPSA and KCNC3
372	are located in the chromosome 19 and were reported in the latest HGI meta-analysis <sup>19</sup> .
373	All mapped genes from analyses conducted in AMR populations are shown in Figure 5.
374	
375	Genetic architecture of COVID-19 hospitalization in AMR populations
376	Allele frequencies of rs13003835 and rs77599934 across ancestries

Neither rs13003835 (*BAZ2B*) nor rs77599934 (*DDIAS*) were significantly associated in
the COVID-19 HGI B2 cross-population or population-specific meta-analyses. Thus,
we investigated their allele frequencies (AF) across populations and compared their
effect sizes.

According to gnomAD v3.1.2, the T allele at rs13003835 (BAZ2B) has an AF of 43% in 381 382 admixed AMR groups, while AF is lower in the EUR populations (16%) and in the 383 global sample (29%). Local ancestry inference (LAI) reported by gnomAD shows that 384 within the Native-American component, the risk allele T is the major allele, whereas it 385 is the minor allele within the African and European LAI components. These large 386 differences in AF might be the reason underlying the association found in AMR populations. However, when comparing effect sizes between populations, we found that 387 388 they were in opposite directions between SAS-AMR and EUR-AFR-EAS and that there was large heterogeneity among them (Figure 3). We queried SNPs within 50kb 389

390 windows of the lead variant in each of the other populations that had p-value<0.01. The variant with the lowest p-value in the EUR population was rs559179177 ( $p=1.72 \times 10^{-4}$ ), 391 which is in perfect LD  $(r^2=1)$  in the 1KGP EUR population with our sentinel variant 392 (rs13003835), and in moderate LD  $r^2=0.4$  in AMR populations. Since this variant was 393 394 absent from the AMR analysis, probably due to its low frequency, it could not be meta-395 analyzed. Power calculations revealed that the EUR analysis was underpowered for this 396 variant to achieve genome-wide significance (77.6%, assuming an effect size of 0.46, 397 EAF= 0.0027, and number of cases/controls as shown in the HGI website for B2-EUR). 398 In the cross-population meta-analysis (B2-ALL), rs559179177 obtained a p-value of  $5.9 \times 10^{-4}$ . 399

rs77599934 (DDIAS) had an AF of 1.1% for the G allele in the nonhospitalized 400 401 controls (Table 2), in line with the recorded gnomAD AF of 1% in admixed AMR 402 groups. This variant has the potential to be a population-specific variant, given the allele frequencies in other population groups, such as EUR (0% in Finnish, 0.025% in non-403 404 Finnish), EAS (0%) and SAS (0.042%), and its greater effect size over AFR populations 405 (Figure 3). Examining the LAI, the G allele occurs at a 10.8% frequency in the African component, while it is almost absent in the Native-American and European. Due to its 406 407 low MAF, rs77599934 was not analyzed in the COVID-19 HGI B2 cross-population meta-analysis and was only present in the HGI B2 AFR population-specific meta-408 409 analysis, precluding the comparison (Figure 3). For this reason, we retrieved the variant 410 with the lowest p-value within a 50 kb region around rs77599934 in the COVID-19 411 HGI cross-population analysis to investigate whether it was in moderate-to-strong LD 412 with our sentinel variant. The variant with the smallest p-value was rs75684040  $(OR=1.07, 95\% CI=1.03-1.12, p=1.84x10^{-3})$ . However, LD calculations using the 1KGP 413 phase 3 dataset indicated that rs77599934 and rs75684040 were poorly correlated 414

415  $(r^2=0.11)$ . As for AFR populations, the variant with the lowest p-value was rs138860115 416  $(p=8.3 \times 10^{-3})$ , but it was not correlated with the lead SNP of this locus.

417

418 *Cross-population meta-analyses* 

419 We carried out two cross-ancestry inverse variance-weighted fixed-effects meta-420 analyses with the admixed AMR GWAS meta-analysis results to evaluate whether the 421 discovered risk loci replicated when considering other population groups. In doing so, 422 we also identified novel cross-population COVID-19 hospitalization risk loci.

First, we combined the SCOURGE Latin American GWAS results with the HGI B2 ALL analysis (supplementary Table 11). We refer to this analysis as the SC-HGI<sub>ALL</sub> meta-analysis. Out of the 40 genome-wide significant loci associated with COVID-19 hospitalization in the last HGI release<sup>1</sup>, this study replicated 39, and the association was stronger than in the original study in 29 of those (supplementary Table 12). However, the variant rs13003835 located in *BAZ2B* did not replicate (OR=1.00, 95% CI=0.98-1.03, p=0.644).

430 In this cross-ancestry meta-analysis, we replicated two associations that were not found in HGIv7, albeit they were sentinel variants in the latest GenOMICC meta-analysis<sup>2</sup>. 431 432 We found an association at the CASC20 locus led by the variant rs2876034 (OR=0.95, 95% CI=0.93-0.97, p=2.83x10<sup>-8</sup>). This variant is in strong LD with the sentinel variant 433 of that study (rs2326788,  $r^2=0.92$ ), which was associated with critical COVID-19<sup>2</sup>. In 434 addition, this meta-analysis identified the variant rs66833742 near ZBTB7A associated 435 with COVID-19 hospitalization (OR=0.94, 95% CI=0.92-0.96, p=2.50x10<sup>-8</sup>). Notably, 436 rs66833742 or its perfect proxy rs67602344 ( $r^2=1$ ) are also associated with upregulation 437

438 of *ZBTB7A* in whole blood and in esophageal mucosa. This variant was previously
439 associated with COVID-19 hospitalization<sup>2</sup>.

440 In a second analysis, we also explored the associations across the defined admixed AMR, EUR, and AFR ancestral sources by combining through meta-analysis the 441 442 SCOURGE Latin American GWAS results with the HGI studies in EUR, AFR, and admixed AMR and excluding those from EAS and SAS (supplementary Table 13). We 443 refer to this as the SC-HGI<sub>3POP</sub> meta-analysis. The association at rs13003835 (BAZ2B, 444 445 OR=1.01, 95% CI=0.98-1.03, p=0.605) was not replicated, and rs77599934 near DDIAS 446 could not be assessed, although the association at the ZBTB7A locus was confirmed (rs66833742, OR=0.94, 95% CI=0.92-0.96, p=1.89x10<sup>-8</sup>). The variant rs76564172 447 located near CREBBP also reached statistical significance (OR=1.31, 95% CI=1.25-448 1.38,  $p=9.64 \times 10^{-9}$ ). The sentinel variant of the region linked to *CREBBP* (in the trans-449 450 ancestry meta-analysis) was also subjected a Bayesian fine mapping (supplementary 451 Table 6). Eight variants were included in the credible set for the region in chromosome 452 16 (meta-analysis SC-HGI<sub>3POP</sub>).

#### 453 Polygenic risk score models

Using the 49 variants associated with disease severity that are shared across populations 454 according to the HGIv7, we constructed a polygenic risk score (PGS) model to assess its 455 generalizability in the admixed AMR (supplementary Table 14). First, we calculated the 456 PGS for the SCOURGE Latin Americans and explored the association with COVID-19 457 458 hospitalization under a logistic regression model. The PGS model was associated with a 1.48-fold increase in COVID-19 hospitalization risk per every PGS standard deviation. 459 460 It also contributed to explaining a slightly larger variance ( $\Delta R = 1.07\%$ ) than the 461 baseline model.

Subsequently, we divided the individuals into PGS deciles and percentiles to assess their risk stratification. The median percentile among controls was 40, while in cases, it was 63. Those in the top PGS decile exhibited a 2.89-fold (95% CI=2.37-3.54,  $p=1.29x10^{-7}$ ) greater risk compared to individuals in the deciles between 4 and 6 (corresponding to a score of the median distribution).

We also examined the distribution of PGS scores across a 5-level severity scale to 467 further determine if there was any correspondence between clinical severity and genetic 468 469 risk. Median PGS scores were lower in the asymptomatic and mild groups, whereas 470 higher median scores were observed in the moderate, severe, and critical patients 471 (Figure 4). We fitted a multinomial model using the asymptomatic class as a reference 472 and calculated the OR for each category (supplementary Table 15), observing that the 473 disease genetic risk was similar among asymptomatic, mild, and moderate patients. 474 Given that the PGS was built with variants associated with critical disease and/or 475 hospitalization and that the categories severe and critical correspond to hospitalized 476 patients, these results underscore the ability of cross-ancestry PGS for risk stratification even in an admixed population. 477

478

#### 479 **DISCUSSION**

We have conducted the largest GWAS meta-analysis of COVID-19 hospitalization in admixed AMR to date. While the genetic risk basis discovered for COVID-19 is largely shared among populations, trans-ancestry meta-analyses on this disease have primarily included EUR samples. This dominance of GWAS in Europeans and the subsequent bias in sample sizes can mask population-specific genetic risks (i.e., variants that are monomorphic in some populations) or be less powered to detect risk variants having

higher allele frequencies in population groups other than Europeans. In this sense, after combining data from admixed AMR patients, we found two risk loci that were first discovered in a GWAS of Latin American populations. Interestingly, the sentinel variant rs77599934 in the *DDIAS* gene is a rare coding variant (~1% for allele G) with a large effect on COVID-19 hospitalization that is nearly monomorphic in most of the other populations. This has likely led to its exclusion from the cross-population metaanalyses conducted to date, remaining undetectable.

493 Fine mapping of the region harboring DDIAS did not reveal further information about 494 which gene could be the more prone to be causal or about the functional consequences 495 of the risk variant, but our sentinel variant was in strong LD with an eOTL that associated with reduced gene expression of DDIAS in the lung. DDIAS, known as 496 497 damage-induced apoptosis suppressor gene, is itself a plausible candidate gene. It has been linked to DNA damage repair mechanisms: research has shown that depletion of 498 DDIAS leads to an increase in ATM phosphorylation and the formation of p53-binding 499 500 protein (53BP1) foci, a known biomarker of DNA double-strand breaks, suggesting a potential role in double-strand break repair<sup>20</sup>. Interestingly, a study found that infection 501 by SARS-CoV-2 also triggered the phosphorylation of ATM kinase and inhibited repair 502 mechanisms, causing the accumulation of DNA damage<sup>21</sup>. This gene has also been 503 proposed as a potential biomarker for lung cancer after finding that it interacts with 504 STAT3 in lung cancer cells, regulating  $IL-6^{22,23}$  and thus mediating inflammatory 505 506 processes, while another study determined that its blockade inhibited lung cancer cell growth<sup>24</sup>. Another prioritized gene from this region was *PRCP*, an angiotensinase which 507 508 shares substrate specificity with ACE2 receptor. It has been positively linked to hypertension and some studies have raised hypotheses on its role in COVID-19 509 progression, particularly in relation to the development of pro-thrombotic events <sup>25,26</sup>. 510

511 The risk region found in chromosome 2 harbors more than one gene. The lead variant 512 rs13003835 is located within BAZ2B, and it increases the expression of the antisense 513 BAZ2B gene in whole blood. BAZ2B encodes one of the regulatory subunits of the Imitation switch (ISWI) chromatin remodelers<sup>27</sup> constituting the BRF-1/BRF-5 514 complexes with SMARCA1 and SMARCA5, respectively. Interestingly, it was 515 discovered that *lnc-BAZ2B* promotes macrophage activation through regulation of 516 BAZ2B expression. Its over-expression resulted in pulmonary inflammation and 517 elevated levels of MUC5AC in mice with asthma<sup>28</sup>. This variant was also an eQTL for 518 519 LY75 (encoding lymphocyte antigen 75) in the esophageal mucosa tissue. Lymphocyte 520 antigen 75 is involved in immune processes through antigen presentation in dendritic cells and endocytosis<sup>29</sup> and has been associated with inflammatory diseases, 521 representing a compelling candidate for the region. Increased expression of LY75 has 522 been detected within hours after infection by SARS-CoV-2<sup>30,31</sup>. It is worth noting that 523 524 differences in AF for this variant suggest that analyses in AMR populations might be more powered to detect the association, supporting the necessity of population-specific 525 studies. 526

527 A third novel risk region was observed on chromosome 15 between the *IQGAP1* and 528 *ZNF774 genes*, although it did not reach genome-wide significance.

Secondary analyses revealed five TWAS-associated genes, some of which have already been linked to severe COVID-19. In a comprehensive multitissue gene expression profiling study<sup>32</sup>, decreased expression of *CAMP* and *S100A8/S100A9* genes in patients with severe COVID-19 was observed, while another study detected the upregulation of *SCL25A37* among patients with severe COVID-19<sup>33</sup>. *SMARCC1* is a subunit of the SWI/SNF chromatin remodeling complex that has been identified as proviral for SARS-CoV-2 and other coronavirus strains through a genome-wide screen<sup>34</sup>. This complex is

crucial for *ACE2* expression and viral entry into the cell<sup>35</sup>. However, it should be noted
that using eQTL mostly from European populations such as those in GTEx could result
in reduced power to detect associations.

To explore the genetic architecture of the trait among admixed AMR populations, we 539 540 performed two cross-ancestry meta-analyses including the SCOURGE Latin American 541 cohort GWAS findings. We found that the two novel risk variants were not associated with COVID-19 hospitalization outside the population-specific meta-analysis, 542 543 highlighting the importance of complementing trans-ancestry meta-analyses with group-544 specific analyses. Notably, this analysis did not replicate the association at the DSTYK 545 locus, which was associated with severe COVID-19 in Brazilian individuals with higher European admixture<sup>36</sup>. This lack of replication aligns with the initial hypothesis of that 546 547 study suggesting that the risk haplotype was derived from European populations, as we reduced the weight of this ancestral contribution in our study by excluding those 548 individuals. 549

550 Moreover, these cross-ancestry meta-analyses pointed to three loci that were not 551 genome-wide significant in the HGIv7 ALL meta-analysis: a novel locus at CREBBP 552 and two loci at ZBTB7A and CASC20 that were reported in another meta-analysis. CREBBP and ZBTB7A achieved a stronger significance when considering only the 553 554 EUR, AFR, and admixed AMR GIA groups. According to a recent study, elevated levels of the ZBTB7A gene promote a quasihomeostatic state between coronaviruses and 555 host cells, preventing cell death by regulating oxidative stress pathways<sup>37</sup>. This gene is 556 involved in several signaling pathways, such as B and T-cell differentiation<sup>38</sup>. On a 557 558 separate note, *CREBBP* encodes the CREB binding protein (CBP), which is involved in transcriptional activation and is known to positively regulate the type I interferon 559 response through virus-induced phosphorylation of IRF-3<sup>39</sup>. In addition, the 560

561 CREBP/CBP interaction has been implicated in SARS-CoV-2 infection<sup>40</sup> via the 562 cAMP/PKA pathway. In fact, cells with suppressed *CREBBP* gene expression exhibit 563 reduced replication of the so-called Delta and Omicron SARS-CoV-2 variants<sup>40</sup>.

We developed a cross-population PGS model, which effectively stratified individuals 564 565 based on their genetic risk and demonstrated consistency with the clinical severity classification of the patients. Only a few polygenic scores were derived from COVID-566 19 GWAS data. Horowitz et al. (2022)<sup>41</sup> developed a score using 6 and 12 associated 567 568 variants (PGS ID: PGP000302) and reported an associated OR (top 10% vs rest) of 1.38 569 for risk of hospitalization in European populations, whereas the OR for Latin-American 570 populations was 1.56. Since their sample size and the number of variants included in the 571 PGS were lower, direct comparisons are not straightforward. Nevertheless, our analysis 572 provides the first results for a PRS applied to a relatively large AMR cohort, being of value for future analyses regarding PRS transferability. 573

This study is subject to limitations, mostly concerning sample recruitment and 574 composition. The SCOURGE Latino-American sample size is small, and the GWAS is 575 576 likely underpowered. Another limitation is the difference in case control recruitment across sampling regions that, yet controlled for, may reduce the ability to observe 577 significant associations driven by different compositions of the populations. In this 578 sense, the identified risk loci might not replicate in a cohort lacking any of the parental 579 580 population sources from the three-way admixture. Likewise, we could not explicitly 581 control for socioenvironmental factors that could have affected COVID-19 spread and 582 hospitalization rates, although genetic principal components are known to capture 583 nongenetic factors. Finally, we must acknowledge the lack of a replication cohort. We 584 used all the available GWAS data for COVID-19 hospitalization in admixed AMR in this meta-analysis due to the low number of studies conducted. Therefore, we had no 585

studies to replicate or validate the results. These concerns may be addressed in the future by including more AMR GWAS in the meta-analysis, both by involving diverse populations in study designs and by supporting research from countries in Latin America.

This study provides novel insights into the genetic basis of COVID-19 severity, emphasizing the importance of considering host genetic factors by using non-European populations, especially of admixed sources. Such complementary efforts can pin down new variants and increase our knowledge on the host genetic factors of severe COVID-19.

#### 595 Materials and methods

#### 596 GWAS in Latin Americans from SCOURGE

#### 597 The SCOURGE Latin American cohort

598 A total of 3,729 COVID-19-positive cases were recruited across five countries from Latin America (Mexico, Brazil, Colombia, Paraguay, and Ecuador) by 13 participating 599 centers (supplementary Table 1) from March 2020 to July 2021. In addition, we 600 601 included 1,082 COVID-19-positive individuals recruited between March and December 602 2020 in Spain who either had evidence of origin from a Latin American country or 603 showed inferred genetic admixture between AMR, EUR, and AFR (with < 0.05%604 SAS/EAS). These individuals were excluded from a previous SCOURGE study that focused on participants with European genetic ancestries<sup>16</sup>. We used hospitalization as a 605 proxy for disease severity and defined COVID-19-positive patients who underwent 606 607 hospitalization as a consequence of the infection as cases and those who did not need 608 hospitalization due to COVID-19 as controls.

Samples and data were collected with informed consent after the approval of the Ethics
and Scientific Committees from the participating centers and by the Galician Ethics
Committee Ref 2020/197. Recruitment of patients from IMSS (in Mexico, City) was
approved by the National Committee of Clinical Research from Instituto Mexicano del
Seguro Social, Mexico (protocol R-2020-785-082).

Samples and data were processed following normalized procedures. The REDCap electronic data capture tool<sup>42,43</sup>, hosted at Centro de Investigación Biomédica en Red (CIBER) from the Instituto de Salud Carlos III (ISCIII), was used to collect and manage demographic, epidemiological, and clinical variables. Subjects were diagnosed with COVID-19 based on quantitative PCR tests (79.3%) or according to clinical (2.2%) or laboratory procedures (antibody tests: 16.3%; other microbiological tests: 2.2%).

### 620 SNP array genotyping

Genomic DNA was obtained from peripheral blood and isolated using the Chemagic
DNA Blood 100 kit (PerkinElmer Chemagen Technologies GmbH), following the
manufacturer's recommendations.

Samples were genotyped with the Axiom Spain Biobank Array (Thermo Fisher
Scientific) following the manufacturer's instructions in the Santiago de Compostela
Node of the National Genotyping Center (CeGen-ISCIII; http://www.usc.es/cegen).
This array contains probes for genotyping a total of 757,836 SNPs. Clustering and
genotype calling were performed using Axiom Analysis Suite v4.0.3.3 software.

629 *Quality control steps and variant imputation* 

A quality control (QC) procedure using PLINK 1.9<sup>44</sup> was applied to both samples and
the genotyped SNPs. We excluded variants with a minor allele frequency (MAF) <1%,</li>
a call rate <98%, and markers strongly deviating from Hardy-Weinberg equilibrium</li>

expectations ( $p < 1 \times 10^{-6}$ ) with mid-p adjustment. We also explored the excess of 633 heterozygosity to discard potential cross-sample contamination. Samples missing >2% 634 635 of the variants were filtered out. Subsequently, we kept the autosomal SNPs, removed high-LD regions and conducted LD pruning (windows of 1,000 SNPs, with a step size 636 of 80 and a  $r^2$  threshold of 0.1) to assess kinship and estimate the global ancestral 637 638 proportions. Kinship was evaluated based on IBD values, removing one individual from 639 each pair with PI HAT>0.25 that showed a Z0, Z1, and Z2 coherent pattern (according 640 to the theoretical expected values for each relatedness level). Genetic principal 641 components (PCs) were calculated with PLINK with the subset of LD pruned variants.

Genotypes were imputed with the TOPMed version r2 reference panel (GRCh38) using the TOPMed Imputation Server, and variants with Rsq<0.3 or with MAF<1% were filtered out. A total of 4,348 individuals and 10,671,028 genetic variants were included in the analyses.

#### 646 *Genetic admixture estimation*

Global genetic inferred ancestry (GIA), referred to the genetic similarity to the used 647 reference individuals, was estimated with ADMIXTURE<sup>45</sup> v1.3 software following a 648 649 two-step procedure. First, we randomly sampled 79 European (EUR) and 79 African (AFR) samples from The 1000 Genomes Project (1KGP)<sup>46</sup> and merged them with the 650 79 Native American (AMR) samples from Mao et al.<sup>47</sup> keeping the biallelic SNPs. LD-651 pruned variants were selected from this merge using the same parameters as in the QC. 652 653 We then run an unsupervised analysis with K=3 to redefine and homogenize the clusters 654 and to compose a refined reference for the analyses by applying a threshold of  $\geq 95\%$  of belonging to a particular cluster. As a result, 20 AFR, 18 EUR, and 38 AMR individuals 655 656 were removed. The same LD-pruned variants data from the remaining individuals were

medRxiv preprint doi: https://doi.org/10.1101/2023.08.11.23293871; this version posted July 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

657 merged with the SCOURGE Latin American cohort to perform supervised clustering 658 and estimate admixture proportions. A total of 471 samples from the SCOURGE cohort 659 with >80% estimated European GIA were removed to reduce the weight of the 660 European ancestral component, leaving a total of 3,512 admixed Latin American 661 (AMR) subjects for downstream analyses.

662 Association analysis

The results for the SCOURGE Latin American GWAS were obtained by testing for 663 664 COVID-19 hospitalization as a surrogate of severity. To accommodate the continuum of 665 GIA in the cohort, we opted for a joint testing of all the individuals as a single study 666 using a mixed regression model, as this approach has demonstrated a greater power and sufficient control of population structure<sup>48</sup>. The SCOURGE cohort consisted of 3,512 667 COVID-19-positive patients: cases (n=1,625) were defined as hospitalized COVID-19 668 patients, and controls (n=1,887) were defined as nonhospitalized COVID-19-positive 669 670 patients.

Logistic mixed regression models were fitted using the SAIGEgds<sup>49</sup> package in R, which implements the two-step mixed SAIGE<sup>50</sup> model methodology and the SPA test. Baseline covariables included sex, age (continuous), and the first 10 PCs. To account for potential heterogeneity in the recruitment and hospitalization criteria across the participating countries, we adjusted the models by groups of the recruitment areas classified into six categories: Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain. This dataset has not been used in any previously published GWAS of COVID-19.

#### 678 Meta-analysis of Latin American populations

The results of the SCOURGE Latin American cohort were meta-analyzed with the AMR HGI-B2 data, conforming our primary analysis. Summary results from the HGI

freeze 7 B2 analysis corresponding to the admixed AMR population were obtained from the public repository (April 8, 2022: <u>https://www.covid19hg.org/results/r7/</u>), summing up 3,077 cases and 66,686 controls from seven contributing studies. We selected the B2 phenotype definition because it offered more power, and the presence of population controls not ascertained for COVID-19 does not have a drastic impact on the association results.

The meta-analysis was performed using an inverse-variance weighting method in METAL<sup>51</sup>. The average allele frequency was calculated, and variants with low imputation quality (Rsq<0.3) were filtered out, leaving 10,121,172 variants for metaanalysis.

Heterogeneity between studies was evaluated with Cochran's Q test. The inflation ofresults was assessed based on a genomic control (lambda).

#### 693 *Replicability of associations*

694 The model-based method MAMBA<sup>52</sup> was used to calculate the posterior probabilities

of replication for each of the lead variants. Variants with  $p<1x10^{-05}$  were clumped and

696 combined with random pruned variants from the 1KGP AMR reference panel. Then,

697 MAMBA was applied to the set of significant and non-significant variants.

Each of the lead variants was also tested for association with the main comorbidities in the SCOURGE cohort with logistic regression models (adjusted by the same base covariables as the GWAS).

#### 701 Definition of the genetic risk loci and putative functional impact

#### 702 Definition of lead variant and novel loci

703 To define the lead variants in the loci that were genome-wide significant, LD-clumping was performed on the meta-analysis data using a threshold p-value $<5x10^{-8}$ , clump 704 distance=1500 kb, independence set at a threshold  $r^2=0.1$  and the SCOURGE cohort 705 genotype data as the LD reference panel. Independent loci were deemed as a novel 706 finding if they met the following criteria: 1) p-value $<5x10^{-8}$  in the meta-analysis and p-707 708 value>5x10<sup>-8</sup> in the HGI B2 ALL meta-analysis or in the HGI B2 AMR and AFR and 709 EUR analyses when considered separately; 2) Cochran's Q-test for heterogeneity of 710 effects is  $<0.05/N_{loci}$ , where N<sub>loci</sub> is the number of independent variants with p $<5x10^{-8}$ ; 711 and 3) the nearest gene has not been previously described in the latest HGIv7 update.

712 Annotation and initial mapping

Functional annotation was performed with FUMA<sup>53</sup> for those variants with a p-713 value $<5x10^{-8}$  or in moderate-to-strong LD (r<sup>2</sup>>0.6) with the lead variants, where the LD 714 was calculated from the 1KGP AMR panel. Genetic risk loci were defined by collapsing 715 LD blocks within 250 kb. Then, genes, scaled CADD v1.4 scores, and RegulomeDB 716 v1.1 scores were annotated for the resulting variants with ANNOVAR in FUMA<sup>53</sup>. 717 Gene-based analysis was also performed using MAGMA<sup>54</sup> as implemented in FUMA 718 under the SNP-wide mean model using the 1KGP AMR reference panel. Significance 719 was set at a threshold  $p < 2.66 \times 10^{-6}$  (which assumes that variants can be mapped to a total 720 721 of 18,817 genes).

FUMA allowed us to perform initial gene mapping by two approaches: (1) positional mapping, which assigns variants to genes by physical distance using 10-kb windows; and (2) eQTL mapping based on GTEx v.8 data from whole blood, lungs, lymphocytes, and esophageal mucosa tissues, establishing a false discovery rate (FDR) of 0.05 to declare significance for variant-gene pairs.

727 Subsequently, to assign the variants to the most likely gene driving the association, we

refined the candidate genes by fine mapping the discovered regions

#### 729 Bayesian fine-mapping

730 To conduct a Bayesian fine mapping, credible sets for the genetic loci considered novel 731 findings were calculated on the results from each of the three meta-analyses to identify a subset of variants most likely containing the causal variant at the 95% confidence level, 732 733 assuming that there is a single causal variant and that it has been tested. We used 734 corrcoverage (https://cran.rstudio.com/web/packages/corrcoverage/index.html) for R to 735 calculate the posterior probabilities of the variant being causal for all variants with a 736  $r^{2}$ >0.1 with the leading SNP and within 1 Mb except for the novel variant in 737 chromosome 19, for which we used a window of 0.5 Mb. Variants were added to the 738 credible set until the sum of the posterior probabilities was  $\geq 0.95$ .

#### 739 *VEP and V2G annotation*

740 We used the Variant-to-Gene (V2G) score to prioritize the genes that were most likely affected by the functional evidence based on expression quantitative trait loci (eQTL), 741 742 chromatin interactions, in silico functional predictions, and distance between the prioritized variants and transcription start site (TSS), based on data from the Open 743 Targets Genetics portal<sup>55</sup>. Details of the data integration and the weighting of each of 744 745 the datasets are described with detail here: https://genetics-docs.opentargets.org/our-746 approach/data-pipeline. V2G is a score for ranking the functional genomics evidence 747 that supports the connection between variants and genes (the higher the score the more 748 likely the variant to be functionally implicated on the assigned gene). We used VEP 749 release 111 (URL: https://www.ensembl.org/info/docs/tools/vep/index.html; accessed

April 10, 2024) <sup>56</sup> to annotate the following: gene symbol, function (exonic, intronic,

751 intergenic, non-coding RNA, etc.), impact, feature type, feature, and biotype.

We queried the GWAS Catalog (date of accession: 01/07/2024) for evidence of association of each of the prioritized genes with traits related to lung diseases or phenotypes. Lastly, those which were linked to COVID-19, infection, or lung diseases in the revised literature were classified as "literature evidence".

#### 756 Transcription-wide association studies

757 Transcriptome-wide association studies (TWAS) were conducted using the pretrained prediction models with MASHR-computed effect sizes on GTEx v8 datasets<sup>57,58</sup>. The 758 759 results from the Latin American meta-analysis were harmonized and integrated with the prediction models through S-PrediXcan<sup>59</sup> for lung, whole blood, lymphocyte and 760 esophageal mucosal tissues. Statistical significance was set at p-value<0.05 divided by 761 the number of genes that were tested for each tissue. Subsequently, we leveraged results 762 for all 49 tissues and ran a multitissue TWAS to improve the power for association, as 763 demonstrated recently<sup>60</sup>. TWAS was also performed using recently published gene 764 expression datasets derived from a cohort of African Americans, Puerto Ricans, and 765 Mexican Americans (GALA II-SAGE)<sup>61</sup>. 766

767

#### 768 Cross-population meta-analyses

We conducted two additional meta-analyses to investigate the ability of combining populations to replicate our discovered risk loci. This methodology enabled the comparison of effects and the significance of associations in the novel risk loci between the results from analyses that included or excluded other population groups.

The first meta-analysis comprised the five populations analyzed within HGI (B2-ALL). Additionally, to evaluate the three GIA components within the SCOURGE Latin American cohort<sup>62</sup>, we conducted a meta-analysis of the admixed AMR, EUR, and AFR cohorts (B2). All summary statistics were retrieved from the HGI repository. We applied the same meta-analysis methodology and filters as in the admixed AMR metaanalysis.

#### 779 Cross-population Polygenic Risk Score

A polygenic risk score (PGS) for critical COVID-19 was derived by combining the variants associated with hospitalization or disease severity that have been discovered to date. We curated a list of lead variants that were 1) associated with either severe disease or hospitalization in the latest HGIv7 release<sup>1</sup> (using the hospitalization weights) or 2) associated with severe disease in the latest GenOMICC meta-analysis<sup>2</sup> that were not reported in the latest HGI release. A total of 48 markers were used in the PGS model (see supplementary Table 13) since two variants were absent from our study.

787 Scores were calculated and normalized for the SCOURGE Latin American cohort with 788 PLINK 1.9. This cross-ancestry PGS was used as a predictor for hospitalization 789 (COVID-19-positive patients who were hospitalized vs. COVID-19-positive patients 790 who did not necessitate hospital admission) by fitting a logistic regression model. 791 Prediction accuracy for the PGS was assessed by performing 500 bootstrap resamples of 792 the increase in the pseudo-R-squared. We also divided the sample into deciles and 793 percentiles to assess risk stratification. The models were fit for the dependent variable 794 adjusting for sex, age, the first 10 PCs, and the sampling region (in the Admixed AMR 795 cohort) with and without the PGS, and the partial pseudo-R2 was computed and 796 averaged among the resamples.

797 A clinical severity scale was used in a multinomial regression model to further evaluate 798 the power of this cross-ancestry PGS for risk stratification. These severity strata were 799 defined as follows: 0) asymptomatic; 1) mild, that is, with symptoms, but without 800 pulmonary infiltrates or need of oxygen therapy; 2) moderate, that is, with pulmonary 801 infiltrates affecting <50% of the lungs or need of supplemental oxygen therapy; 3) 802 severe disease, that is, with hospital admission and PaO<sub>2</sub><65 mmHg or SaO<sub>2</sub><90%, 803 PaO<sub>2</sub>/FiO<sub>2</sub><300, SaO<sub>2</sub>/FiO<sub>2</sub><440, dyspnea, respiratory frequency 22 bpm, and 804 infiltrates affecting >50% of the lungs; and 4) critical disease, that is, with an admission 805 to the ICU or need of mechanical ventilation (invasive or noninvasive).

806 Data availability

Summary statistics from the SCOURGE Latin American GWAS and the analysis scripts
are available from the public repository https://github.com/CIBERER/ScourgeCOVID19.

810

#### 811 Funding

Instituto de Salud Carlos III (COV20\_00622 to A.C., COV20/00792 to M.B., 812 COV20\_00181 to C.A., COV20\_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.); 813 814 European Union (ERDF) 'A way of making Europe'. Fundación Amancio Ortega, Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association 815 816 (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140 817 818 'Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19' to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 819 820 to C.F.).

821 SD-DA was supported by a Xunta de Galicia predoctoral fellowship.

#### 822 Author contributions

- 823 Study design: RC, AC, CF. Data collection: SCOURGE cohort group. Data analysis:
- 824 SD-DA, RC, ADL, CF, JML-S. Interpretation: SD-DA, RC, ADL. Drafting of the
- 825 manuscript: SD-DA, RC, ADL, CF, AR-M, AC. Critical revision of the manuscript:
- SD-DA, RC, ADL, AC, CF, JAR, AR-M, and PL. Approval of the final version of the
- 827 publication: all coauthors.

#### 828 Acknowledgments

- 829 The contribution of the Centro National de Genotipado (CEGEN) and Centro de
- 830 Supercomputación de Galicia (CESGA) for funding this project by providing
- supercomputing infrastructures is also acknowledged. The authors are also particularly
- grateful for the supply of material and the collaboration of patients, health professionals
- from participating centers and biobanks. Namely, Biobanc-Mur, and biobancs of the
- 834 Complexo Hospitalario Universitario de A Coruña, Complexo Hospitalario
- Universitario de Santiago, Hospital Clínico San Carlos, Hospital La Fe, Hospital
- 836 Universitario Puerta de Hierro Majadahonda—Instituto de Investigación Sanitaria
- 837 Puerta de Hierro—Segovia de Arana, Hospital Ramón y Cajal, IDIBGI, IdISBa, IIS
- 838 Biocruces Bizkaia, IIS Galicia Sur. Also biobanks of the Sistema de Salud de Aragón,
- 839 Sistema Sanitario Público de Andalucía, and Banco Nacional de ADN.

840

# 841 **References**

- 842 1. Initiative, T. C.-19 H. G. & Ganna, A. A second update on mapping the human genetic
- architecture of COVID-19. 2022.12.24.22283874 Preprint at
- 844 https://doi.org/10.1101/2022.12.24.22283874 (2023).

845 2. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 |
846 Nature. https://www.nature.com/articles/s41586-023-06034-3.

847 3. Niemi, M. E. K. *et al.* Mapping the human genetic architecture of COVID-19. *Nature*848 600, 472–477 (2021).

849 4. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* 538, 161–164
850 (2016).

5. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic Studies. *Cell* **177**, 26–31 (2019).

6. Li, Y. R. & Keating, B. J. Trans-ethnic genome-wide association studies: advantages and challenges of mapping in diverse populations. *Genome Med.* **6**, 91 (2014).

855 7. Rosenberg, N. A. *et al.* Genome-wide association studies in diverse populations. *Nat.*856 *Rev. Genet.* 11, 356–366 (2010).

8. Kwok, A. J., Mentzer, A. & Knight, J. C. Host genetics and infectious disease: new tools,
insights and translational opportunities. *Nat. Rev. Genet.* 22, 137–153 (2021).

859 9. Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious
860 disease in human populations. *Nat. Rev. Genet.* 15, 379–393 (2014).

10. Namkoong, H. *et al.* DOCK2 is involved in the host genetics and biology of severe COVID-19. *Nature* **609**, 754–760 (2022).

Bastard, P. *et al.* A loss-of-function IFNAR1 allele in Polynesia underlies severe viral
diseases in homozygotes. *J. Exp. Med.* 219, e20220028 (2022).

Buncan, C. J. A. *et al.* Life-threatening viral disease in a novel form of autosomal
recessive IFNAR2 deficiency in the Arctic. *J. Exp. Med.* **219**, e20212427 (2022).

Peterson, R. E. *et al.* Genome-wide Association Studies in Ancestrally Diverse
Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589–603
(2019).

Mester, R. *et al.* Impact of cross-ancestry genetic architecture on GWAS in admixed
populations. 2023.01.20.524946 Preprint at https://doi.org/10.1101/2023.01.20.524946
(2023).

Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and
to boost power | Nature Genetics. https://www.nature.com/articles/s41588-020-00766-y.

875 16. Cruz, R. *et al.* Novel genes and sex differences in COVID-19 severity. *Hum. Mol. Genet.*876 **31**, 3789–3806 (2022).

17. Degenhardt, F. *et al.* Detailed stratified GWAS analysis for severe COVID-19 in four
European populations. *Hum. Mol. Genet.* **31**, 3945–3966 (2022).

879 18. Whole-genome sequencing reveals host factors underlying critical COVID-19 | Nature.
880 https://www.nature.com/articles/s41586-022-04576-6.

Kanai, M. *et al.* A second update on mapping the human genetic architecture of
COVID-19. *Nature* 621, E7–E26 (2023).

Evolution-based screening enables genome-wide prioritization and discovery of DNA
 repair genes | PNAS. https://www.pnas.org/doi/full/10.1073/pnas.1906559116.

885 21. Gioia, U. *et al.* SARS-CoV-2 infection induces DNA damage, through CHK1 degradation
886 and impaired 53BP1 recruitment, and cellular senescence. *Nat. Cell Biol.* **25**, 550–564 (2023).

887 22. Im, J.-Y. *et al.* DDIAS promotes STAT3 activation by preventing STAT3 recruitment to
888 PTPRM in lung cancer cells. *Oncogenesis* 9, 1–11 (2020).

889 23. Im, J.-Y., Kang, M.-J., Kim, B.-K. & Won, M. DDIAS, DNA damage-induced apoptosis
890 suppressor, is a potential therapeutic target in cancer. *Exp. Mol. Med.* 1–7 (2023)
891 doi:10.1038/s12276-023-00974-6.

Human Noxin is an anti-apoptotic protein in response to DNA damage of A549
non-small cell lung carcinoma - Won - 2014 - International Journal of Cancer - Wiley Online
Library. https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600.

89525.Angeli, F. *et al.* The spike effect of acute respiratory syndrome coronavirus 2 and896coronavirus disease 2019 vaccines on blood pressure. *Eur. J. Intern. Med.* **109**, 12–21 (2023).

Silva-Aguiar, R. P. *et al.* Role of the renin-angiotensin system in the development of
severe COVID-19 in hypertensive patients. *Am. J. Physiol.-Lung Cell. Mol. Physiol.* **319**, L596–
L602 (2020).

27. Li, Y. *et al.* The emerging role of ISWI chromatin remodeling complexes in cancer. *J. Exp. Clin. Cancer Res.* **40**, 346 (2021).

28. Xia, L. *et al.* Inc-BAZ2B promotes M2 macrophage activation and inflammation in
children with asthma through stabilizing BAZ2B pre-mRNA. *J. Allergy Clin. Immunol.* **147**, 921932.e9 (2021).

90529.The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance906Antigen Presentation via Major Histocompatibility Complex Class II–Positive Lysosomal

907 Compartments | Journal of Cell Biology | Rockefeller University Press.

https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis Dec.

91030.Sims, A. C. et al. Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear911Import Block Enhances Host Transcription in Human Lung Cells. J. Virol. 87, 3885–3902 (2013).

912 31. A Network Integration Approach to Predict Conserved Regulators Related to

913 Pathogenicity of Influenza and SARS-CoV Respiratory Viruses | PLOS ONE.

914 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374.

915 32. Gómez-Carballa, A. *et al.* A multi-tissue study of immune gene expression profiling
916 highlights the key role of the nasal epithelium in COVID-19 severity. *Environ. Res.* 210, 112890
917 (2022).

918 33. Policard, M., Jain, S., Rego, S. & Dakshanamurthy, S. Immune characterization and
919 profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS920 CoV-2 oncogenesis mechanism. *Virus Res.* **301**, 198464 (2021).

34. Wei, J. *et al.* Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2
Infection. *Cell* 184, 76-91.e13 (2021).

923 35. Wei, J. *et al.* Pharmacological disruption of mSWI/SNF complex activity restricts SARS924 CoV-2 infection. *Nat. Genet.* 55, 471–483 (2023).

925 36. Pereira, A. C. *et al.* Genetic risk factors and COVID-19 severity in Brazil: results from
926 BRACOVID study. *Hum. Mol. Genet.* **31**, 3021–3031 (2022).

37. Zhu, X. *et al.* ZBTB7A promotes virus-host homeostasis during human coronavirus 229E
infection. *Cell Rep.* 41, 111540 (2022).

38. Gupta, S. *et al.* Emerging role of ZBTB7A as an oncogenic driver and transcriptional
repressor. *Cancer Lett.* 483, 22–34 (2020).

931 39. Yoneyama, M. *et al.* Direct triggering of the type I interferon system by virus infection:
932 activation of a transcription factor complex containing IRF-3 and CBP/p300. *EMBO J.* **17**, 1087–
933 1095 (1998).

40. Yang, Q. *et al.* SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMPdependent pathways. *J. Med. Virol.* **95**, e28383 (2023).

Horowitz, J. E. *et al.* Genome-wide analysis provides genetic evidence that ACE2
influences COVID-19 risk and yields risk scores associated with severe disease. *Nat. Genet.* 54, 382–392 (2022).

42. Harris, P. A. *et al.* Research electronic data capture (REDCap)—A metadata-driven
methodology and workflow process for providing translational research informatics support. *J. Biomed. Inform.* 42, 377–381 (2009).

43. Harris, P. A. *et al.* The REDCap consortium: Building an international community of
software platform partners. *J. Biomed. Inform.* **95**, 103208 (2019).

944 44. Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population945 Based Linkage Analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).

45. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in
unrelated individuals. *Genome Res.* 19, 1655–1664 (2009).

948 46. Auton, A. *et al.* A global reference for human genetic variation. *Nature* 526, 68–74
949 (2015).

47. Mao, X. *et al.* A Genomewide Admixture Mapping Panel for Hispanic/Latino
Populations. *Am. J. Hum. Genet.* **80**, 1171–1178 (2007).

48. Wojcik, G. L. *et al.* Genetic analyses of diverse populations improves discovery for
complex traits. *Nature* 570, 514–518 (2019).

49. Zheng, X. & Davis, J. W. SAIGEgds—an efficient statistical tool for large-scale PheWAS
with mixed models. *Bioinformatics* 37, 728–730 (2021).

956 50. Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample

957 relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).

958 51. METAL: fast and efficient meta-analysis of genomewide association scans |

959 Bioinformatics | Oxford Academic.

960 https://academic.oup.com/bioinformatics/article/26/17/2190/198154.

961 52. McGuire, D. *et al.* Model-based assessment of replicability for genome-wide

association meta-analysis. *Nat. Commun.* **12**, 1964 (2021).

963 53. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and 964 annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).

96554.MAGMA: Generalized Gene-Set Analysis of GWAS Data | PLOS Computational Biology.966https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219.

967 55. Ghoussaini, M. *et al.* Open Targets Genetics: systematic identification of trait968 associated genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* 49,
969 D1311–D1320 (2021).

970 56. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).

971 57. Barbeira, A. N. *et al.* Exploiting the GTEx resources to decipher the mechanisms at
972 GWAS loci. *Genome Biol.* 22, 49 (2021).

973 58. Barbeira, A. N. *et al.* GWAS and GTEx QTL integration. Zenodo

974 https://doi.org/10.5281/zenodo.3518299 (2019).

Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene
expression variation inferred from GWAS summary statistics. *Nat. Commun.* 9, 1825 (2018).

977 60. Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues 978 improves association detection. *PLOS Genet.* **15**, e1007889 (2019).

61. Kachuri, L. *et al.* Gene expression in African Americans, Puerto Ricans and Mexican
Americans reveals ancestry-specific patterns of genetic architecture. *Nat. Genet.* 55, 952–963
(2023).

98262.Genome-wide patterns of population structure and admixture among Hispanic/Latino983populations | PNAS. https://www.pnas.org/doi/10.1073/pnas.0914618107?url\_ver=Z39.88-

984 2003&rfr\_id=ori:rid:crossref.org&rfr\_dat=cr\_pub%20%200pubmed.

985

986

987

- 988
- 989

990

991



997

#### Non Hospitalized Hospitalized Variable N = 1,887N = 1,625 $54.1 \pm 14.5$ Age – mean years $\pm$ SD $39.1 \pm 11.9$ Sex - N (%) Female (%) 1253 (66.4) 668 (41.1) GIA\* - % mean ±SD European $54.4 \pm 16.2$ $39.4 \pm 20.7$ African $15.3\pm12.7$ $9.1 \pm 11.6$ Native American $30.3\pm19.8$ $51.3\pm26.5$ Comorbidities - N (%) Vascular/endocrinological 488 (25.9) 888 (64.5) Cardiac 60 (3.2) 151 (9.3) Nervous 15 (0.8) 61 (3.8) Digestive 14 (0.7) 33 (2.0) Onco-hematological 21 (1.1) 48 (3.00) 76 (4.0) Respiratory 118 (7.3)

#### 998 Table 1. Demographic characteristics of the SCOURGE Latin American cohort.

999 \*Global genetic inferred ancestry.

### 1000 Table 2. Lead independent variants in the admixed AMR GWAS meta-analysis.

SNP reID	chr:pos	EA	NEA	OR (95% CI)	P-value	EAF	EAF	Noavost aono	Mamba
5111 1510						cases	controls	weuresi gene	PIP
rs13003835	2:159407982	Т	С	1.20 (1.12-1.27)	3.66E-08	0.563	0.429	BAZ2B	0.30
rs35731912	3:45848457	Т	С	1.65 (1.47-1.85)	6.30E-17	0.087	0.056	LZTFL1	0.95

rs2477820	6:41535254	А	Т	0.84 (0.79-0.89)	1.89E-08	0.453	0.517	FOXP4-AS1	0.18
rs77599934	11:82906875	G	А	2.27 (1.7-3.04)	2.26E-08	0.016	0.011	DDIAS	0.95

1002

1003

1004

# 1005 Table 3. Novel variants in the SC-HGI<sub>ALL</sub> and SC-HGI<sub>3POP</sub> meta-analyses (with

1006 **respect to HGIv7).** Independent signals after LD clumping.

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	Nearest gene	Analysis
rs76564172	16:3892266	Т	G	1.31 (1.19-1.44)	9.64E-09	CREBBP	SC-HGI <sub>3POP</sub>
rs66833742	19:4063488	Т	С	0.94 (0.92-0.96)	1.89E-08	ZBTB7A	SC-HGI <sub>3POP</sub>
rs66833742	19:4063488	Т	С	0.94 (0.92-0.96)	2.50E-08	ZBTB7A	SC-HGI <sub>ALL</sub>
rs2876034	20:6492834	А	Т	0.95 (0.93-0.97)	2.83E-08	CASC20	SC-HGI <sub>ALL</sub>

1007 EA: effect allele; NEA: non-effect allele.

# 1008 Figure 1. Flow chart of this study.



1009

1010

# Figure 2. A) Manhattan plot for the admixed AMR GWAS meta-analysis. 1011 Probability thresholds at $p=5x10^{-8}$ and $p=5x10^{-5}$ are indicated by the horizontal lines. 1012 1013 Genome-wide significant associations with COVID-19 hospitalizations were found on 1014 chromosome 2 (within BAZ2B), chromosome 3 (within LZTFL1), chromosome 6 (within FOXP4), and chromosome 11 (within DDIAS). A Quantile Quantile plot is 1015 shown in supplementary Figure 2. B) Regional association plots for rs1003835 at 1016 1017 chromosome 2 and rs77599934 at chromosome 11; C) Allele frequency distribution across the 1000 Genomes Project populations for the lead variants rs1003835 and 1018 rs77599934. Retrieved from The Geography of Genetic Variants Web or GGV. 1019



#### 1026

Figure 3. Forest plot showing effect sizes and the corresponding confidence
intervals for the sentinel variants identified in the AMR meta-analysis across
populations. All beta values with their corresponding CIs were retrieved from the B2
population-specific meta-analysis from the HGI v7 release, except for AMR, for which
the beta value and IC from the HGI<sub>AMR</sub>-SCOURGE meta-analysis are represented.

1032



- 1035 Figure 4. (A) Polygenic risk stratified by PGS deciles comparing each risk group
- against the lowest risk group (OR-95% CI); (B) Distribution of the PGS scores in
- 1037 each of the severity scale classes . 0-Asymptomatic, 1-Mild disease, 2-Moderate
- 1038 disease, 3-Severe disease, 4-Critical disease.







1041

#### 1043 Figure 5. Summary of the results from gene prioritization strategies used for

- 1044 genetic associations in AMR populations. GWAS catalog association for BAZ2B-AS
- 1045 was with FEV/FCV ratio. Literature based evidence is further explored in discussion.

